Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial (Q46675364)

24 December 2017

title

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial (English)

1 reference

24 December 2017

schizophreniform disorder

main subject

schizophrenia

0 references

1 reference

16

Joseph Peuskens

1 reference

24 December 2017

5

Yvonne Vergouwe

0 references

Anita Riecher-Rössler

18

Anita Riecher-Rössler

0 references

Jan Libiger

Jan Libiger

10

0 references

Silvana Galderisi

Silvana Galderisi

9

0 references

René S. Kahn

1

René S Kahn

1 reference

24 December 2017

Diederick Grobbee

19

Diederick E Grobbee

1 reference

24 December 2017

Janusz Rybakowski

8

Janusz K Rybakowski

1 reference

24 December 2017

author name string

W Wolfgang Fleischhacker

2

1 reference

24 December 2017

Han Boter

3

1 reference

24 December 2017

Michael Davidson

4

1 reference

24 December 2017

Yvonne Vergouwe

5

1 reference

24 December 2017

Ireneus P M Keet

6

1 reference

24 December 2017

Mihai D Gheorghe

7

1 reference

24 December 2017

Martina Hummer

11

1 reference

24 December 2017

Sonia Dollfus

12

1 reference

24 December 2017

Juan J López-Ibor

13

1 reference

24 December 2017

Luchezar G Hranov

14

1 reference

24 December 2017

Wolfgang Gaebel

15

1 reference

24 December 2017

Nils Lindefors

17

1 reference

24 December 2017

EUFEST study group

20

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

24 December 2017

number of pages

13

1 reference

inferred from page(s)

published in

The Lancet

1 reference

24 December 2017

volume

371

1 reference

24 December 2017

issue

9618

1 reference

24 December 2017

page(s)

1085-1097

1 reference

24 December 2017

A meta-analysis of the efficacy of second-generation antipsychotics

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Reliability and validity of a depression rating scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Application and results of the Manchester Short Assessment of Quality of Life (MANSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Further evidence of a dose-response threshold for haloperidol in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

The relationship between D 2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Compliance therapy in psychotic patients: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Multilevel time series models with applications to repeated measures data.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Olanzapine and haloperidol in first episode psychosis: two-year data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

Sex differences in the risk of schizophrenia: evidence from meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960486-9

7 January 2021

10.1016/S0140-6736(08)60486-9

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18374841

1 reference

24 December 2017